We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Research · September 09, 2021

Evaluating Anti–Acetylated Peptide Antibodies for Early Rheumatoid Arthritis Diagnosis

Therapeutic Advances in Musculoskeletal Disease


Additional Info

Therapeutic Advances in Musculoskeletal Disease
Presence of Anti-Acetylated Peptide Antibodies (AAPA) in Inflammatory Arthritis and Other Rheumatic Diseases Suggests Discriminative Diagnostic Capacity Towards Early Rheumatoid Arthritis
Ther Adv Musculoskelet Dis 2021 Jul 23;[EPub Ahead of Print], P Studenic , A Alunno, D Sieghart, H Bang, D Aletaha, S Blüml, H Haslacher, J S Smolen, R Gerli, G Steiner

Further Reading